Utilizing this molecularly engineered system, Bellavia and colleagues successfully delivered BCR-ABL siRNA to CML cells, making them more sensitive to imatinib therapy in a CML mouse model. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.